Menu Search
Equities

ALK-Abello A/S

4AJ0:FRA

ALK-Abello A/S

Actions
  • Price (EUR)21.50
  • Today's Change-0.32 / -1.47%
  • Shares traded125.00
  • 1 Year change+109.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 05 2024 14:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.

  • Revenue in DKK (TTM)5.18bn
  • Net income in DKK690.00m
  • Incorporated1961
  • Employees2.81k
  • Location
    ALK-Abello A/SBoege Alle 6-8HOERSHOLM 2970DenmarkDNK
  • Phone+45 45747576
  • Fax+45 45748690
  • Websitehttps://www.alk.net/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ALK B:CPH since
announced		Transaction
value
AllerQuest LLC-PRE-PENDeal completed02 Jan 202402 Jan 2024Deal completed57.71%--
Data delayed at least 15 minutes, as of Nov 05 2024 16:10 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.